HSD17B4 and hepatocellular carcinoma: By the way, in 2025, Zhang et al. demonstrated that in lenvatinib-induced ferroptosis of hepatocellular carcinoma (HCC) cells, deltex E3 ubiquitin ligase 2 (DTX2)-mediated degradation of hydroxysteroid (17β) dehydrogenase 4 (HSD17B4) reprograms lipid metabolism by suppressing docosahexaenoic acid (DHA) biosynthesis, thereby attenuating ferroptosis [29].